SeaStar Medical Holding Corporation ICU

Company Overview

SeaStar Medical Holding Corporation is a U.S.-based medical technology company focused on developing extracorporeal therapies designed to reduce the consequences of excessive inflammation in critically ill patients. The company operates within the biotechnology, medical device, and critical care healthcare industries, with a primary emphasis on therapies targeting hyperinflammation associated with acute kidney injury (AKI), sepsis, and other life-threatening inflammatory conditions. Its core technology platform centers on the Selective Cytopheretic Device (SCD), a cell-directed immunomodulatory therapy intended to selectively target activated immune cells during extracorporeal blood circulation.

The company’s principal revenue and development driver has been the advancement and commercialization efforts surrounding the QUELIMMUNE therapy platform and related SCD technologies. SeaStar Medical primarily serves hospitals, intensive care units, pediatric critical care providers, and nephrology-focused treatment centers. The company traces its origins to research into immune modulation and extracorporeal blood purification technologies and later became publicly traded through a business combination transaction involving a special purpose acquisition company (SPAC). Its strategic positioning is tied to addressing unmet medical needs in critically ill patient populations where treatment options remain limited and mortality rates are high.